AnaptysBio collects royalties from the cancer treatment Jemperli and the psoriasis treatment Quimilza, which partners GSK and Vanda sell. It last closed at $46.63 on Nov 20, down 1.62% on the day. The next earnings report for ANAB is expected around Tue, Mar 2, 2027, after the close. For the quarter ended Sep 2026, ANAB reported EPS of $0.11 on revenue of $30.3M, with revenue down 60.3% from a year ago. Over its last 8 reports the stock moved an average of 6.3% the session after earnings. Over the last 12 months ANAB insiders bought $17.2M of stock on the open market and sold $9.8M, according to SEC Form 4 filings.
AI Auto Pilots
Is ANAB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ANAB.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on ANABStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
ANAB · as of the Nov 20 close · updated each morning
Downtrend
The stock is 2% below its 20 day and 5% below its 50 day average. It is 21% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 45). The nearest support is the Pivot S1 at $45.88, and the nearest resistance the Pivot at $46.80.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityLow, 4.4%/day
Key levels
$73.3052 week high+57.2%
$56.44200 day average+21.0%
$53.12100 day average+13.9%
$49.00Swing high (Nov 4)+5.1%
$48.8850 day average+4.8%
$47.5820 day average+2.0%
$47.54Pivot R1+2.0%
$46.80Pivot+0.4%
$46.63Last close
$45.88Pivot S1−1.6%
$45.01Swing low (Nov 6)−3.5%
$33.1052 week low−29.0%
Indicators
RSI (14)
45.50
Middle of its range
Neutral
MACD
-0.63
Above its signal line
Bullish
Stochastic
49.1
Middle of its range
Neutral
ADX (14)
21.2
Weak trend
Williams %R
-60.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
-49.0
Oversold below −100, overbought above 100
Neutral
Rate of change
+0.4%
Change over 10 sessions
Bullish
ATR (14)
$2.07
Typical daily range, 4.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityLow, 12.2%/day
Key levels
$73.3052 week high+57.2%
$56.44200 day average+21.0%
$53.12100 day average+13.9%
$49.00Swing high (Nov 4)+5.1%
$48.8850 day average+4.8%
$47.5820 day average+2.0%
$47.54Pivot R1+2.0%
$46.80Pivot+0.4%
$46.63Last close
$45.88Pivot S1−1.6%
$45.01Swing low (Nov 6)−3.5%
$33.1052 week low−29.0%
Indicators
RSI (14)
40.84
Middle of its range
Neutral
MACD
-2.52
Below its signal line
Bearish
Stochastic
14.9
Near the bottom of its range
Oversold
ADX (14)
15.3
No clear trend
Williams %R
-84.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-91.0
Oversold below −100, overbought above 100
Neutral
Rate of change
−13.4%
Change over 10 sessions
Bearish
ATR (14)
$5.70
Typical daily range, 12.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for ANAB
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ANAB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow ANAB usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for ANABHow many large options trades hit ANAB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in ANAB in the last 90 days.
From SEC Form 4 filings by ANAB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANAB is in one of them and how their past ANAB trades turned out.
AnaptysBio is a pharmaceutical company based in San Diego, California, whose business centers on collecting royalties from medicines it has licensed to others. It receives royalties on Jemperli, a cancer treatment developed and sold by GSK, and on Quimilza, a treatment for generalized pustular psoriasis that Vanda Pharmaceuticals is developing and commercializing. The company does not develop or sell these products itself, so its payments depend on the sales of its partners.